---
title: "Health and Economic Impact of Scaling Monthly Oral PrEP (MK-8527) Versus Injectable Lenacapavir in"
id: "medrxiv-10-modeling-the-health-and-economic-impact-of-scaling-up-monthly-oral-pre-exposure"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-modeling-the-health-and-economic-impact-of-scaling-up-monthly-oral-pre-exposure"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.01.26361983v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Health and Economic Impact of Scaling Monthly Oral PrEP (MK-8527) Versus Injectable Lenacapavir in
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-modeling-the-health-and-economic-impact-of-scaling-up-monthly-oral-pre-exposure
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.01.26361983v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This modeling study used the agent-based network model EMOD-HIV to simulate scale-up of monthly oral PrEP (MK-8527), injectable **lenacapavir**, and combined long-acting PrEP strategies in western Kenya and South Africa from 2026–2035. - Scenarios compared MK-8527 alone, lenacapavir alone, and combined approaches to a baseline of daily oral PrEP only, with uptake varied among female sex workers, their male clients, and people with >1 partner. - Effectiveness assumptions: **MK-8527** 95% effectiveness for 2 months (assuming individuals took 2 of 3 pills dispensed); **lenacapavir** 95% effectiveness for 6 months. - With equal uptake, MK-8527 averted fewer infections than lenacapavir in both countries (MK-8527: 6–14% infections averted; lenacapavir: 11–18% infections averted) but had substantially lower provision costs. - Cost-per-pill scenarios for MK-8527 modeled at US$1.00 and US$2.50; at US$1.00 per pill MK-8527 provision costs were 58–59% lower than lenacapavir, and 40–43% lower at US$2.50 per pill. - In western Kenya, incremental cost-effectiveness ratios (ICERs) for MK-8527 alone were US$467/DALY averted (US$1.00/pill) and US$799/DALY averted (US$2.50/pill); lenacapavir’s ICER was US$1,306/DALY averted. - In South Africa, all long-acting PrEP strategies were modeled as cost-saving over a 35-year horizon, although near-term budget impacts were substantial (US$169–348 million over five years). - Service delivery composed the majority of MK-8527 costs (≈73% when pill price = US$1.00). - Combined lenacapavir + MK-8527 strategies increased infections averted (13–23%) but raised provision costs above either strategy alone. - Authors conclude MK-8527 can reduce HIV incidence at lower costs than lenacapavir but its cost-effectiveness depends on low pill prices (e.g., US$1.00/pill) and targeting to populations at high HIV risk.
## Clinical Analysis & Structured Key Points
Modeling the health and economic impact of scaling up monthly oral pre-exposure prophylaxis alone or alongside injectable Lenacapavir in Kenya and South Africa | medRxiv Skip to main content Modeling the health and economic impact of scaling up monthly oral pre-exposure prophylaxis alone or alongside injectable Lenacapavir in Kenya and South Africa Akash Malhotra , View ORCID Profile Nishali Patel , View ORCID Profile David Kaftan , View ORCID Profile Edinah Mudimu , View ORCID Profile Anna Bershteyn , Monisha Sharma doi: https://doi.org/10.64898/2026.09.01.26361983 Akash Malhotra 1 University of Washington; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nishali Patel 1 University of Washington; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nishali Patel David Kaftan 2 New York University Grossman School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for David Kaftan Edinah Mudimu 3 University of South Africa Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Edinah Mudimu Anna Bershteyn 2 New York University Grossman School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Anna Bershteyn Monisha Sharma 1 University of Washington; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: msharma1{at}uw.edu Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Introduction: Monthly oral HIV pre-exposure prophylaxis (PrEP) such as MK-8527 offer promise as low-cost, self-administered options that are easily delivered through community-based platforms. Economic evaluations of MK-8527 either alone or alongside other long-acting (LA) PrEP products like lenacapavir are needed for informing HIV prevention strategies. Methods: We adapted an agent-based network model, EMOD-HIV, to simulate LA-PrEP scale-up in South Africa and western Kenya from 2026-2035; scenarios evaluated MK-8527 alone, lenacapavir alone and combined strategies, with varying uptake among female sex workers, their male clients, and individuals with >1 partner. We assumed 95% effectiveness of MK-8527 for 2 months (assuming individuals took 2 of 3 pills dispensed) and 95% lenacapavir effectiveness for 6 months. Scenarios were compared to a baseline of daily oral PrEP only. Results: Assuming the same uptake rates, MK-8527 alone achieved lower health impacts than lenacapavir alone in both settings (6-14% vs. 11-18% of HIV infections averted) but had substantially lower costs; provision costs of MK-8527 were 58-59% lower than lenacapavir assuming $1.00/pill and 40-43% lower at $2.50/pill. In western Kenya, ICERs for MK-8527 alone were $467/DALY averted and $799/DALY averted assuming pill prices of $1.00 and $2.50 respectively, compared to $1,306/DALY averted for lenacapavir. In South Africa, all LA-PrEP strategies were cost-saving over the 35-year horizon, although near-term budget impacts were substantial ($169-348 million over five years). Service delivery accounted for the majority of MK-8527 costs (73% at $1.00 per pill). Combined strategies of lenacapavir and MK-8527 increased health benefits (13-23% infections averted) but had higher provision costs than either strategy alone. Conclusion: MK-8527 can reduce HIV incidence at lower costs than lenacapavir. However, high service delivery costs limit its cost-effectiveness to scenarios in which pill prices are low (US$1.00 per pill) and provision is targeted to populations at substantial HIV risk. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Funder Information Declared Gates Foundation, https://ror.org/0456r8d26 , INV-038274 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Back to top Previous Next Posted September 04, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Modeling the health and economic impact of scaling up monthly oral pre-exposure prophylaxis alone or alongside injectable Lenacapavir in Kenya and South Africa Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Modeling the health and economic impact of scaling up monthly oral pre-exposure prophylaxis alone or alongside injectable Lenacapavir in Kenya and South Africa Akash Malhotra , Nishali Patel , David Kaftan , Edinah Mudimu , Anna Bershteyn , Monisha Sharma medRxiv 2026.09.01.26361983; doi: https://doi.org/10.64898/2026.09.01.26361983 Share This Article: Copy Citation Tools Modeling the health and economic impact of scaling up monthly oral pre-exposure prophylaxis alone or alongside injectable Lenacapavir in Kenya and South Africa Akash Malhotra , Nishali Patel , David Kaftan , Edinah Mudimu , Anna Bershteyn , Monisha Sharma medRxiv 2026.09.01.26361983; doi: https://doi.org/10.64898/2026.09.01.26361983 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (615) Allergy and Immunology (896) Anesthesia (327) Cardiovascular Medicine (4776) Dentistry and Oral Medicine (476) Dermatology (410) Emergency Medicine (645) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1617) Epidemiology (15853) Forensic Medicine (32) Gastroenterology (1196) Genetic and Genomic Medicine (6996) Geriatric Medicine (727) Health Economics (1059) Health Informatics (4998) Health Policy (1428) Health Systems and Quality Improvement (1741) Hematology (583) HIV/AIDS (1338) Infectious Diseases (except HIV/AIDS) (16251) Intensive Care and Critical Care Medicine (1162) Medical Education (665) Medical Ethics (151) Nephrology (721) Neurology (7207) Nursing (365) Nutrition (1074) Obstetrics and Gynecology (1233) Occupational and Environmental Health (1002) Oncology (3581) Ophthalmology (1039) Orthopedics (393) Otolaryngology (448) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1781) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5844) Public and Global Health (9705) Radiology and Imaging (2392) Rehabilitation Medicine and Physical Therapy (1436) Respiratory Medicine (1245) Rheumatology (635) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (769) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [HBsAg clearance and occult HBV mutation in HIV/HBV-coinfected patients on ART](https://medichelpline.com/clinical-feed/medrxiv-7-hepatitis-b-surface-antigen-clearance-in-hiv-hbv-coinfected-patients-associated.md)
- [Urine-based Mtb antigen detection for childhood TB using an ultrasensitive ECL immunoassay](https://medichelpline.com/clinical-feed/medrxiv-16-the-accuracy-of-urine-based-mycobacterial-antigens-to-detect-childhood.md)
- [Nicotine metabolism rate and myocardial infarction risk in people with HIV who smoke](https://medichelpline.com/clinical-feed/plos-one-12-rate-of-nicotine-metabolism-on-risk-of-myocardial-infarction-among-people-with.md)
- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.